Immunotherapy: Big Pharma’s Seductive Embrace

The oncology community believes that immunotherapy will be foundational, in the same way that combination chemotherapy became the backbone of treatment in the 1970s. The marching order is to trial broadly, quickly, making clinical development particularly well-suited for Big Pharma.

More from Deal-Making

More from In Vivo